BNP Paribas Easy MSCI World SRI S-Series PAB 5% Capped UCITS ETF EUR Capitalisation is a equity ETF from BNP Paribas tracking the MSCI World SRI S-Series PAB 5% Capped index through physical replication. Domiciled in Luxembourg and launched in 2017, the fund manages about 910 M € and charges a TER of 0.26% — 26 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
BNP Paribas Easy MSCI World SRI S-Series PAB 5% Capped UCITS ETF EUR Capitalisation competes with 1 other products on the same index (MSCI World SRI S-Series PAB 5% Capped): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.26% against a group median of 0.26%. It has been listed since 2017, 9 years of track record.
On a €10,000 investment the TER costs 26 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 22.3% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Luxembourg, which determines the tax treatment of income received by the fund and the supervisory authority.
| NVIDIA Corporation | 5.9% |
| ASML Holding N.V. | 3.3% |
| Analog Devices Inc | 3.1% |
| Tesla Inc | 1.8% |
| Advanced Micro Devices Inc | 1.6% |
| Visa Inc. Class A | 1.5% |
| Tokyo Electron Limited | 1.4% |
| American Tower Corp | 1.3% |
| Novartis AG | 1.2% |
| The Bank of New York Mellon Corporation | 1.2% |
| Borsa Italiana | EMWE | EUR |
| XETRA | EMWE | EUR |
| Francoforte | EMWE | EUR |
| Euronext Paris | EMWE | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.